Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: Interleukin-1β, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-α, the soluble tumor necrosis factor receptors I and II, and α1-antichymotrypsin

Alzheimer Disease and Associated Disorders

Volumn 12, Issue 3, 1998, Pages 215-227

  Lanzrein, Anne Sophie ^a,b   Johnston, Carole M ^a   Perry, V Hugh ^a   Jobst, Kim A ^a   King, Elizabeth M ^a   Smith, A David ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alzheimer disease; Brain tissue; Cerebrospinal fluid; Cytokines; Serum

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN TISSUE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENTORHINAL CORTEX; HUMAN; HUMAN TISSUE; LONGITUDINAL STUDY; NEUROPATHOLOGY; PRIORITY JOURNAL; TEMPORAL LOBE;

EID: 0032406078     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199809000-00016     Document Type: Article

References (59)

1. 1-antichymotrypsin in the brain of Alzheimer s disease. Cell 1988;52:487-501.
2. 1-Antichymotrypsin is associated solely with amyloid deposits containing the β-protein. Amyloid and cell locaization of α 1-antichymotrypsin. Neurobiol Aging 1990;11:123-9.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed, rev. Washington, DC: APA Press, 1987.
4. Andersen K., Launer LJ, Ott A, Hoes AW, Breteler MMB, Hofman A. Do nonsteriodal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 1995;45:1441-5.
5. Altstiel LD, Lawlor B, Mohs R, Scheidler J, Dalton A, Metha P, Davis K. Elevated α1-antichymotrypsin serum levels in a subset of non-demented first-degree relatives of Alzheimer's disease patients. Dementia 1995;6:17-20.
6. Araujo DM, Lapchak PA. Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: selective effects on specific interleukins and interleukin receptors. Neuroscience 1994; 61:745-54.
7. 2+ accumulation. Proc Natl Acad Sci USA 1995;92:9328-32.
8. 2-macroglobulin indicate an acute phase state in Alzheimer's disease cortices. FEBS Lett 1991; 285:111-4.
9. Bradford MM. Rapid and sensitive method for quantitation of microgram quantities of proteins utilizing principle of protein-dye binding. Anal Biochem 1976;72:248-54.
10. Breitner JCS, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, Anthony JC. Inverse association of anti-inflammatory treatments and Alzheimer's disease. Initial results of a co-twin study. Neurology 1994;44:227-32.
11. Bruce AJ, Boling W, Kindy MS, Peschon J, Kraemer PJ, Carpenter MK, Holtsberg FW, Mattson MP. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nature Med 1996;2:788-94.
12. 1-antichymotrypsin in Down's syndrome and Alzheimer's disease. Ann Neurol 1992;32:193-7.
13. Cacabelos R, Alvarez XA, Fernández-Novoa L, Franco A, Mangues FR, Pellicer A, Nishimura T. Brain interleukin-1β in Alzheimer's disease and vascular dementia. Methods Find Exp Clin Pharmacol 1994b;16:141-51.
14. Cacabelos R, Alvarez XA, Franco-Maside A, Fernández-Novoa L, Caamaño J. Serum tumor necrosis factor (TNF) in Alzheimer's disease and multi-infarct dementia. Methods Find Exp Clin Pharmacol 1994a;16:29-35.
15. Cacabelos R, Barquero M, Garcia P, Alvarez XA, de Seijas V. Cerebrospinal fluid interleukin-1β (IL-1β) in Alzheimer's disease and neurological disorders. Methods Find Exp Clin Pharmacol 1991a;13:455-8.
16. Cacabelos R, Franco-Maside A, Alvarez XA. Interleukin-1 in Alzheimer's disease and multi-infarct dementia: neuropsychological correlations. Methods Find Exp Clin Pharmacol 1991b;13:703-8.
17. Cheng B, Christakos S, Mattson MP. Tumor necrosis factor protects against excitotoxic/metaboloc insults and promote maintenance of calcium homeostasis. Neuron 1994;12:139-53.
18. Delamarche C, Berger F, Gallard L, Pouplard-Barthelaix A. Aging and Alzheimer's disease: protease inhibitors in cerebrospinal fluid. Neurobiol Aging 1991;12:71-4.
19. Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 1993;7:75-83.
20. Eikelenboom P, Hack CE, Rozemuller JM, Stam FC. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol 1989;56:259-62.
21. Fillit H, Ding W, Buee L, Kalman J, Altsiel L, Lawlor B, Wolf-Klein G. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett 1991;129:318-29.
22. Freedman MS, Muth KL, Trotter JL, Yoshiva CN, Antel JP. Prospective serial analysis of interleukin-2 and soluble interleukin-2 receptor in relapsing-remitting multiple sclerosis. Neurology 1992;42:1596-601.
23. Gallo P, Piccinno MG, Tavalato B, Siden A. A longitudinal study in IL-1, sIL-2R, IL-4 and IFN-gamma in multiple sclerosis CSF and serum. J Neurol Sci 1991;101:227-32.
24. Griffin WST, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolusion. J Neuropathol Exp Neurol 1995;54:276-81.
25. Griffin WST, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, Araoz C. Brain interleukin-1 and S-100 immunoreactivity are elevated in Downs syndrome and Alzheimer's disease. Proc Natl Acad Sci USA 1989;86:7611-5.
26. Haga S, Akai K, Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol (Berl) 1989;77:569-75.
27. Itagaki S. McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease. J Neuroimmunol 1989;24:173-82.
28. Jobst KA, Smith AD, Szatmari M, et al. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 1992;340:1179-83.
29. Jobst KA, Smith AD, Szatmari M, et al. Rapidly progressing atrophy of medial temporal lobe in Alzheimer's disease. Lancet 1994;343:829-30.
30. Kalaria RN. The immunopathology of Alzheimer's disease and some related disorders. Brain Pathol 1993;3:333-47.
31. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42:1097-104.
32. 1rantichymotrypsin is not a useful marker for Alzheimer's disease or dementia in Parkinson's disease. J Neural Transm 1993;6:145-9.
33. Lee SC, Liu, W, Dickson DW, Brosnan CF, Berman JW, Cytokine production by human fetal microglia and astrocytes. J Immunol 1993;150: 2659-67.
34. 1-antichymotrypsin in patients with probable Alzheimer's disease: an acute phase reactant without the peripheral acute phase response. J Neuroimmunol 1995;57:71-5.
35. 1-antichymotrypsin level as a marker for Alzheimer-type dementia. Neurobiol Aging 1995;16:747-53.
36. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 1994:372:92-4.
37. Matsubara E, Hirai S, Amari M, et al. α1-Antichymotrypsin as a possible marker for Alzheimer-type dementia. Ann Neurol 1990;28:561-7.
38. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Activation of the classical complement pathway in brain tissue of Alzheimer's patients. Neurosci Lett 1989;107:341-6.
39. McGeer PL, Kawamata T, Walker DG, Askiyama H, Tooyama I, McGeer E. Microglia in degenerative neurological disease. Glia 1993;7:84-92.
40. McGeer PL, McGeer EG. Complement proteins and complement inhibitors in Alzheimer's disease. Res Immunol 1992;143:621-4.
41. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
42. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease. Neurology 1991;41:479-86.
43. Perry VH, Anderson PB, Gordon S. Macrophages and inflammation in the central nervous system. Trends Neurosci 1993;16:268-73.
44. Peter JB, Boctor FN, Tourtelotte WW. Serum and CSF levels of IL-2, sIL2R, TNF-alpha, and IL-1-beta: expected lack of clinical utility. Neurology 1991;41:121-3.
45. 1-Antichymotrypsin and IL-1β are not increased in CSF or serum in Alzheimer's disease. Neurobiol Aging 1994;15:313-7.
46. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas MD, Brandt D. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995;45:51-5.
47. Rogers J, Kirkby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-11.
48. Roth M, Huppert F, Tim E, Mountjoy CQ. CAMDEX: the Cambridge examination for mental disorders in the elderly. Cambridge, UK: Cambridge University Press, 1988.
49. Rudick RA, Barna BP. Serum interleukin 2 and soluble interleukin 2 receptor in patients. Arch Neurol 1990;47:254-5.
50. Shaw CE, Dunbar PR, Macaulay HA, Neale TJ. Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol 1995;242:53-8.
51. 1-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab Invest 1992;66:223-30.
52. Tierney MC, Fisher RH, Lewis AJ, et al. The NINCDS-ADRA workgroup criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathological study of 57 cases. Neurology 1988;38:359-64.
53. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and terapeutic agent. Annu Rev Med 1994;5:491-503.
54. Van der Poll T, Lowry SF. Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defence? Shock 1995;3:1-12.
55. Van Duijn CM, Hofman A, Nagelkerken L. Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease. Neurosci Lett 1990;108:350-4.
56. Webster S, Glabe C, Rogers J. Multivalent binding of complement protein C1q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Biochem Biophys Res Commun 1995;217:869-75.
57. 2-macroglobulin and C-reactive protein. Brain Res 1993;629:245-52.
58. Yao J, Keri JE, Taffs RE, Colton CA. Characterization of interleukin-1 production by microglia in culture. Brain Res 1992;591:88-93.
59. Zhan S-S, Veerhuis R, Janssen I, Kamphorst W, Eikelenboom, P. Immunohistochemical distribution of the inhibitors of the terminal complement complex in Alzheimer's disease. Neurodegeneration 1994;3: 111-7.